Prothena Gives Amyloidosis Drug Birtamimab A Second Chance
With post hoc analysis from a 2018 study showing a survival benefit in patients at high risk for early mortality, Prothena negotiated a path forward with the US FDA for approval in AL amyloidosis.
You may also be interested in...
Roche is paying Elan spin-out Prothena $45m in the near term as part of a new collaboration to develop and commercialize antibodies that target alpha-synuclein. The agreement includes PRX002, Prothena's monoclonal antibody for the treatment of Parkinson's disease, which is currently in preclinical development and is expected to enter Phase I trials in 2014.
AR-15512 missed the primary endpoints in a Phase IIb dry eye disease study that could have served as a pivotal trial, but Aerie’s drug hit enough signs and symptoms of the disease to justify a Phase III.
The Phase III failure of ampreloxetine in nOH followed disappointing Phase IIb data for izencitinib in ulcerative colitis in August. Theravance narrows focus to respiratory disease, including label expansions for Yupelri.